International Stem Cell Net Income Growth & History (ISCO)
International Stem Cell's net income was −$418,000 for fiscal 2025.
View full International Stem Cell company overviewInternational Stem Cell annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$418,000 | −$209,000 | — |
| 2024 | 2024-12-31 | −$209,000 | −$78,000 | — |
| 2023 | 2023-12-31 | −$131,000 | $200,000 | — |
| 2022 | 2022-12-31 | −$331,000 | $568,000 | — |
| 2021 | 2021-12-31 | −$899,000 | $1.8M | — |
| 2020 | 2020-12-31 | −$2.7M | $1.5M | — |
| 2019 | 2019-12-31 | −$4.3M | −$2.1M | — |
| 2018 | 2018-12-31 | −$2.1M | $3.9M | — |
| 2017 | 2017-12-31 | −$6.1M | −$5.0M | — |
| 2016 | 2016-12-31 | −$1.1M | $1.6M | — |
| 2015 | 2015-12-31 | −$2.6M | $9.8M | — |
| 2014 | 2014-12-31 | −$12.5M | −$2.0M | — |
| 2013 | 2013-12-31 | −$10.5M | −$646,000 | — |
| 2012 | 2012-12-31 | −$9.8M | −$662,000 | — |
| 2011 | 2011-12-31 | −$9.2M | $3.6M | — |
| 2010 | 2010-12-31 | −$12.7M | −$4.2M | — |
| 2009 | 2009-12-31 | −$8.5M | −$1.9M | — |
| 2008 | 2008-12-31 | −$6.6M | −$499,000 | — |
| 2007 | 2007-12-31 | −$6.1M | $512,000 | — |
| 2006 | 2006-12-31 | −$6.6M | — | — |
International Stem Cell quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$71,000 | −$200,000 | — |
| Q1 2026 | 2026-03-31 | −$220,000 | $36,000 | — |
| Q4 2025 | 2025-12-31 | −$348,000 | −$359,000 | — |
| Q3 2025 | 2025-09-30 | $57,000 | $182,000 | — |
| Q2 2025 | 2025-06-30 | $129,000 | $10,000 | +8.40% |
| Q1 2025 | 2025-03-31 | −$256,000 | −$42,000 | — |
| Q4 2024 | 2024-12-31 | $11,000 | $469,000 | — |
| Q3 2024 | 2024-09-30 | −$125,000 | $6,000 | — |
| Q2 2024 | 2024-06-30 | $119,000 | −$373,000 | −75.81% |
| Q1 2024 | 2024-03-31 | −$214,000 | −$180,000 | — |
| Q4 2023 | 2023-12-31 | −$458,000 | −$481,000 | — |
| Q3 2023 | 2023-09-30 | −$131,000 | $212,000 | — |
| Q2 2023 | 2023-06-30 | $492,000 | $494,000 | — |
| Q1 2023 | 2023-03-31 | −$34,000 | −$25,000 | — |
| Q4 2022 | 2022-12-31 | $23,000 | $374,000 | — |
| Q3 2022 | 2022-09-30 | −$343,000 | −$178,000 | — |
| Q2 2022 | 2022-06-30 | −$2,000 | −$218,000 | — |
| Q1 2022 | 2022-03-31 | −$9,000 | $590,000 | — |
| Q4 2021 | 2021-12-31 | −$351,000 | $370,000 | — |
| Q3 2021 | 2021-09-30 | −$165,000 | $379,000 | — |
| Q2 2021 | 2021-06-30 | $216,000 | $1.3M | — |
| Q1 2021 | 2021-03-31 | −$599,000 | −$226,000 | — |
| Q4 2020 | 2020-12-31 | −$721,000 | $2.0M | — |
| Q3 2020 | 2020-09-30 | −$544,000 | −$547,000 | — |
| Q2 2020 | 2020-06-30 | −$1.1M | −$438,000 | — |
| Q1 2020 | 2020-03-31 | −$373,000 | $533,000 | — |
| Q4 2019 | 2019-12-31 | −$2.7M | −$1.7M | — |
| Q3 2019 | 2019-09-30 | $3,000 | −$118,000 | −97.52% |
| Q2 2019 | 2019-06-30 | −$648,000 | −$254,000 | — |
| Q1 2019 | 2019-03-31 | −$906,000 | −$76,000 | — |
| Q4 2018 | 2018-12-31 | −$1.0M | $361,000 | — |
| Q3 2018 | 2018-09-30 | $121,000 | $2.3M | — |
| Q2 2018 | 2018-06-30 | −$394,000 | −$962,000 | — |
| Q1 2018 | 2018-03-31 | −$830,000 | $2.3M | — |
| Q4 2017 | 2017-12-31 | −$1.4M | −$3.5M | — |
| Q3 2017 | 2017-09-30 | −$2.2M | −$2.6M | — |
| Q2 2017 | 2017-06-30 | $568,000 | −$10.4M | −94.80% |
| Q1 2017 | 2017-03-31 | −$3.1M | $11.5M | — |
| Q4 2016 | 2016-12-31 | $2.2M | $3.7M | — |
| Q3 2016 | 2016-09-30 | $414,000 | $953,000 | — |
| Q2 2016 | 2016-06-30 | $10.9M | $10.2M | +1410.24% |
| Q1 2016 | 2016-03-31 | −$14.6M | −$13.3M | — |
| Q4 2015 | 2015-12-31 | −$1.5M | $3.1M | — |
| Q3 2015 | 2015-09-30 | −$539,000 | $1.5M | — |
| Q2 2015 | 2015-06-30 | $723,000 | $5.1M | — |
| Q1 2015 | 2015-03-31 | −$1.3M | $148,000 | — |
| Q4 2014 | 2014-12-31 | −$4.6M | −$1.8M | — |
| Q3 2014 | 2014-09-30 | −$2.0M | $1.8M | — |
| Q2 2014 | 2014-06-30 | −$4.4M | −$2.2M | — |
| Q1 2014 | 2014-03-31 | −$1.4M | $277,000 | — |
| Q4 2013 | 2013-12-31 | −$2.8M | −$170,000 | — |
| Q3 2013 | 2013-09-30 | −$3.8M | −$1.7M | — |
| Q2 2013 | 2013-06-30 | −$2.2M | $277,000 | — |
| Q1 2013 | 2013-03-31 | −$1.7M | $965,000 | — |
| Q4 2012 | 2012-12-31 | −$2.6M | $24,000 | — |
| Q3 2012 | 2012-09-30 | −$2.1M | $484,000 | — |
| Q2 2012 | 2012-06-30 | −$2.5M | −$88,000 | — |
| Q1 2012 | 2012-03-31 | −$2.7M | −$1.1M | — |
| Q4 2011 | 2011-12-31 | −$2.6M | — | — |
| Q3 2011 | 2011-09-30 | −$2.6M | $454,283 | — |
| Q2 2011 | 2011-06-30 | −$2.4M | −$6.6M | — |
| Q1 2011 | 2011-03-31 | −$1.6M | — | — |
| Q3 2010 | 2010-09-30 | −$3.0M | — | — |
| Q2 2010 | 2010-06-30 | $4.2M | — | — |
International Stem Cell net income trends
Over the last five fiscal years, International Stem Cell's net income increased from −$2.7M to −$418,000, a change of $2.3M. The latest reported quarter, Q2 2026, shows −$71,000.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review International Stem Cell source filings ↗